Omron Healthcare has announced its additional investment into AliveCor by its parent company, Omron Corporation, as part of a $65 million series E funding for AI-based personal ECG (electrocardiogram) technology.
The companies continue to build on their alliance to accelerate development of solutions for cardiovascular disease management and remote patient monitoring utilising ECG technology.
Over one billion adults are hypertensive worldwide, and their risk of stroke is nearly five times greater if they also suffer from atrial fibrillation. Hypertension is also an underlying health condition which increases the risk of complications with COVID-19. The ability to monitor both blood pressure and heart rhythm at home is essential for early detection, treatment and management of these cardiovascular health conditions.
Isao Ogino, president and CEO of Omron Healthcare, said: “Omron is committed to developing life-saving cardiovascular health technologies in pursuit of our Going for Zero vision to eliminate heart attacks and strokes. It is a lofty goal and, as we said when we evolved our vision, we cannot do it alone. That is why we seek like-minded partners, like AliveCor, to advance our initiatives and work together to save lives.
“Our alliance with AliveCor will help enhance our current technology portfolio and provide hypertensive patients and healthcare professionals with data that can save lives – a complete picture of patients cardiovascular health that can be achieved with personal remote monitoring technology used at home. We continue to explore and develop new technologies to enhance the accessibility of home monitoring that help people to manage their condition, and will engage partners like AliveCor to ensure this technology is best-in-market, further accelerating our remote patient monitoring business to achieve our goal, Going for Zero.”
Omron expanded its blood pressure monitor portfolio with the launch of Complete, a blood pressure monitor with ECG capability in a single device.
